Токсичность антиретровирусных препаратов для лечения вич−инфекции Medline.ru - медико-биологический информационный портал Медлайн.ру

1. Федеральный научно-методический центр по профилактике и борьбе со СПИДом ФБУН Центрального НИИ эпидемиологии Роспотребнадзора. Справка «ВИЧ-инфекция в Российской Федерации в первом полугодии 2019 г.». - URL: http://aids-centr.perm.ru/images/4/hiv_in_russia/hiv_in_rf_30.06.2019.pdf. (дата обращения: 16.02.2020).

2. Bacchetti P., Gripshover B., Grunfeld C., Heymsfield S., McCreath H., Osmond D., Saag M., Scherzer R., Shlipak M., Tien P., Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIVinfection // J. Acquir. Immune Defic. Syndr. 2005. Vol.40, No. 2. P. 121-131. DOI: 10.1097/01.qai.0000182230.47819.aa

3. Bartlett K., Eaton S. Mitochondrial beta-oxidation // Eur. J. Biochem. 2004. Vol.271, No. 3. P. 462-469. DOI: 10.1046/j.1432-1033.2003.03947.x

4. Cherry C.L., Gahan M.E., McArthur J., Lewin S.R., Hoy J.F., Wesseling S.L. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat // J. Acquir. Immune Defic. Syndr. 2002. Vol. 30, No. 3. P, 271-277. DOI: 10.1097/00126334-200207010-00002

5. Coghlan M.E., Sommadossi J.P., Jhala N.C., Many W.J., Saag M.S., Johnson V.A. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases // Clin. Infect. Dis. 2001. Vol. 33, No. 11. P. 1914-1921. DOI: 10.1086/323783

6. Cossarizza A., Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria // AIDS. 2004. Vol. 18, No. 2. P. 137-151. DOI: 10.1097/00002030-200401230-00002

7. Dalakas M.C. Peripheral neuropathy and antiretroviral drugs // J. Peripher. Nerv. Syst. 2001. Vol. 6, No. 1. P. 14-20. DOI: 10.1046/j.1529-8027.2001.006001014.x

8. Dalakas M.C., Leon-Monzon M.E., Bernardini I., Gahl W.A., Jay C.A. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage // Ann. Neurol. 1994. Vol. 35. No. 4. P. 482-487. DOI: 10.1002/ana.410350418

9. Guidelines on the public health response to pretreatment HIV drug resistance. Geneva: World Health Organization, 2017. 84 p.

10. Hill A.L., Rosenbloom D.I., Fu F., Nowak M.A., Siliciano R.F. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 // Proc. Natl. Acad. Sci. USA. 2014. Vol. 111, No. 37. P. 13475-13480. DOI: 10.1073/pnas.1406663111

11. Kakuda T.N. Pharmacology of nucleoside and nucleotidereverse transcriptase inhibitor-induced mitochondrial toxicity // Clin.Ther. 2000. Vol. 22, No. 6. P. 685-708. DOI: 10.1016/S0149-2918(00)90004-3

12. Lewis W., Day B.J., Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective // Nat. Rev. Drug Discov. 2003. Vol. 2, No. 10. P. 812-822. DOI: 10.1038/nrd1201

13. McArthur J.C., Brew B.J., Nath A. Neurological complications of HIV infection // Lancet Neurol. 2005. Vol. 4, No. 9. P. 543-555. DOI: 10.1016/S1474-4422(05)70165-4

14. McComsey G.A.,Ward D.J., Hessenthaler S.M., SensionM.G., Shalit P., Lonergan J.T., Fisher R.L., Williams V.C., Hernandez J.E. Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL, ESS40010) Study Team. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin. Infect. Dis. 2004. Vol. 38, No. 2. P. 263-270. DOI: 10.1086/380790

15. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity // Clin. Ther. 2000. Vol. 22, No. 8. P. 911-936. DOI: 10.1016/S0149-2918(00)80064-8

16. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D., Investigators H.O.S. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection // New Engl. J. Med. 1998. Vol. 338, No. 13. P. 853-860. DOI: 10.1056/NEJM199803263381301

17. Shikuma C.M., Hu N., Milne C., Yost F., Waslien C., Shimizu S., Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy // AIDS. 2001. Vol. 15, No. 14. P 1801-1809. DOI: 10.1097/00002030-200109280-00009

18. Simpson D.M., Kitch D., Evans S.R., McArthur J.C., Asmuth D.M., Cohen B., Goodkin K., Gerschenson M., So Y., Marra C.M., Diaz-Arrastia R., Shriver S., Millar L., Clifford D.B., ACTG A547 Study Group. HIV neuropathy natural history cohort study: assessment measures and risk factors // Neurology. 2006. Vol. 66, No. 11. P. 1679-1687. DOI: 10.1212/01.wnl.0000218303.48113.5d

19. Simpson D.M., Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection // J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1995. Vol. 9, No. 2. P. 153-161.

20. Wulff E.A., Wang A.K., Simpson D.M. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment // Drugs. 2000. Vol. 59, No. 6. P. 1251-1260. DOI: 10.2165/00003495-200059060-00005

References

1. Federal Scientific and Methodological Center for the Prevention and Control of AIDS of the Central Federal Research Institution of Epidemiology of Rospotrebnadzor. Enquiry «HIV infection in the Russian Federation in the first half of 2019». - URL: http://aids-centr.perm.ru/images/4/hiv_in_russia/hiv_in_rf_30.06.2019.pdf. (date of the application: 16.02.2020) [In Russian].

2. Bacchetti P., Gripshover B., Grunfeld C., Heymsfield S., McCreath H., Osmond D., Saag M., Scherzer R., Shlipak M., Tien P., Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIVinfection. J. Acquir. Immune Defic. Syndr. 2005. Vol.40, No. 2. P. 121-131. DOI: 10.1097/01.qai.0000182230.47819.aa

3. Bartlett K., Eaton S. Mitochondrial beta-oxidation. Eur. J. Biochem. 2004. Vol.271, No. 3. P. 462-469. DOI: 10.1046/j.1432-1033.2003.03947.x

4. Cherry C.L., Gahan M.E., McArthur J., Lewin S.R., Hoy J.F., Wesseling S.L. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J. Acquir. Immune Defic. Syndr. 2002. Vol. 30, No. 3. P, 271-277. DOI: 10.1097/00126334-200207010-00002

5. Coghlan M.E., Sommadossi J.P., Jhala N.C., Many W.J., Saag M.S., Johnson V.A. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin. Infect. Dis. 2001. Vol. 33, No. 11. P. 1914-1921. DOI: 10.1086/323783

6. Cossarizza A., Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS. 2004. Vol. 18, No. 2. P. 137-151. DOI: 10.1097/00002030-200401230-00002

7. Dalakas M.C. Peripheral neuropathy and antiretroviral drugs. J. Peripher. Nerv. Syst. 2001. Vol. 6, No. 1. P. 14-20. DOI: 10.1046/j.1529-8027.2001.006001014.x

8. Dalakas M.C., Leon-Monzon M.E., Bernardini I., Gahl W.A., Jay C.A. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann. Neurol. 1994. Vol. 35. No. 4. P. 482-487. DOI: 10.1002/ana.410350418

9. Guidelines on the public health response to pretreatment HIV drug resistance. Geneva: World Health Organization, 2017. 84 p.

10. Hill A.L., Rosenbloom D.I., Fu F., Nowak M.A., Siliciano R.F. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc. Natl. Acad. Sci. USA. 2014. Vol. 111, No. 37. P. 13475-13480. DOI: 10.1073/pnas.1406663111

11. Kakuda T.N. Pharmacology of nucleoside and nucleotidereverse transcriptase inhibitor-induced mitochondrial toxicity. Clin.Ther. 2000. Vol. 22, No. 6. P. 685-708. DOI: 10.1016/S0149-2918(00)90004-3

12. Lewis W., Day B.J., Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2003. Vol. 2, No. 10. P. 812-822. DOI: 10.1038/nrd1201

13. McArthur J.C., Brew B.J., Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005. Vol. 4, No. 9. P. 543-555. DOI: 10.1016/S1474-4422(05)70165-4

14. McComsey G.A.,Ward D.J., Hessenthaler S.M., SensionM.G., Shalit P., Lonergan J.T., Fisher R.L., Williams V.C., Hernandez J.E. Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL, ESS40010) Study Team. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin. Infect. Dis. 2004. Vol. 38, No. 2. P. 263-270. DOI: 10.1086/380790

15. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin. Ther. 2000. Vol. 22, No. 8. P. 911-936. DOI: 10.1016/S0149-2918(00)80064-8

16. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D., Investigators H.O.S. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl. J. Med. 1998. Vol. 338, No. 13. P. 853-860. DOI: 10.1056/NEJM199803263381301

17. Shikuma C.M., Hu N., Milne C., Yost F., Waslien C., Shimizu S., Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS. 2001. Vol. 15, No. 14. P 1801-1809. DOI: 10.1097/00002030-200109280-00009

18. Simpson D.M., Kitch D., Evans S.R., McArthur J.C., Asmuth D.M., Cohen B., Goodkin K., Gerschenson M., So Y., Marra C.M., Diaz-Arrastia R., Shriver S., Millar L., Clifford D.B., ACTG A547 Study Group. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology. 2006. Vol. 66, No. 11. P. 1679-1687. DOI: 10.1212/01.wnl.0000218303.48113.5d

19. Simpson D.M., Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1995. Vol. 9, No. 2. P. 153-161.

20. Wulff E.A., Wang A.K., Simpson D.M. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs. 2000. Vol. 59, No. 6. P. 1251-1260. DOI: 10.2165/00003495-200059060-00005